25 XP   0   0   10

Li Kang Biomedical Co Ltd
Buy, Hold or Sell?

Let's analyse Li Kang Biomedical Co Ltd together

PenkeI guess you are interested in Li Kang Biomedical Co Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Li Kang Biomedical Co Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Li Kang Biomedical Co Ltd

I send you an email if I find something interesting about Li Kang Biomedical Co Ltd.

Quick analysis of Li Kang Biomedical Co Ltd (30 sec.)










What can you expect buying and holding a share of Li Kang Biomedical Co Ltd? (30 sec.)

How much money do you get?

How much money do you get?
NT$0.00
When do you have the money?
1 year
How often do you get paid?
52.5%

What is your share worth?

Current worth
NT$19.25
Expected worth in 1 year
NT$21.08
How sure are you?
92.5%

+ What do you gain per year?

Total Gains per Share
NT$1.83
Return On Investment
3.4%

For what price can you sell your share?

Current Price per Share
NT$53.80
Expected price per share
NT$51.34 - NT$58.80
How sure are you?
50%

1. Valuation of Li Kang Biomedical Co Ltd (5 min.)




Live pricePrice per Share (EOD)

NT$53.80

Intrinsic Value Per Share

NT$45.99 - NT$54.05

Total Value Per Share

NT$65.24 - NT$73.31

2. Growth of Li Kang Biomedical Co Ltd (5 min.)




Is Li Kang Biomedical Co Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$19.7m$16.5m$2.2m12.0%

How much money is Li Kang Biomedical Co Ltd making?

Current yearPrevious yearGrowGrow %
Making money$868.5k$877.1k-$8.6k-1.0%
Net Profit Margin17.5%16.1%--

How much money comes from the company's main activities?

3. Financial Health of Li Kang Biomedical Co Ltd (5 min.)




4. Comparing to competitors in the Travel Services industry (5 min.)




  Industry Rankings (Travel Services)  


Richest
#54 / 77

Most Revenue
#71 / 77

Most Profit
#44 / 77

What can you expect buying and holding a share of Li Kang Biomedical Co Ltd? (5 min.)

Welcome investor! Li Kang Biomedical Co Ltd's management wants to use your money to grow the business. In return you get a share of Li Kang Biomedical Co Ltd.

What can you expect buying and holding a share of Li Kang Biomedical Co Ltd?

First you should know what it really means to hold a share of Li Kang Biomedical Co Ltd. And how you can make/lose money.

Speculation

The Price per Share of Li Kang Biomedical Co Ltd is NT$53.80. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Li Kang Biomedical Co Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Li Kang Biomedical Co Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is NT$19.25. Based on the TTM, the Book Value Change Per Share is NT$0.46 per quarter. Based on the YOY, the Book Value Change Per Share is NT$0.60 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is NT$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Li Kang Biomedical Co Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 NT$% of Price per ShareNT$% of Price per ShareNT$% of Price per ShareNT$% of Price per ShareNT$% of Price per Share
Usd Eps0.030.1%0.030.1%0.030.0%0.020.0%0.020.0%
Usd Book Value Change Per Share0.030.0%0.010.0%0.020.0%0.010.0%0.010.0%
Usd Dividend Per Share0.000.0%0.000.0%0.020.0%0.030.1%0.020.0%
Usd Total Gains Per Share0.030.0%0.010.0%0.040.1%0.040.1%0.040.1%
Usd Price Per Share1.82-1.92-1.51-1.44-1.54-
Price to Earnings Ratio15.39-18.09-15.40-22.98-24.16-
Price-to-Total Gains Ratio68.58-22.17-41.15-41.49-61.26-
Price to Book Ratio3.03-3.33-2.97-2.92-5.14-
Price-to-Total Gains Ratio68.58-22.17-41.15-41.49-61.26-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.68394
Number of shares593
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.03
Usd Book Value Change Per Share0.010.01
Usd Total Gains Per Share0.010.04
Gains per Quarter (593 shares)8.4923.95
Gains per Year (593 shares)33.9795.81
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
103424771986
20685815537182
301029223256278
4013612630974374
5017016038793470
60204194464111566
70238228541130662
80272262618148758
90306296696167854
100340330773185950

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%37.00.03.092.5%38.00.025.060.3%
Book Value Change Per Share3.01.00.075.0%9.03.00.075.0%15.05.00.075.0%32.08.00.080.0%36.027.00.057.1%
Dividend per Share0.00.04.00.0%7.00.05.058.3%14.00.06.070.0%21.00.019.052.5%21.00.042.033.3%
Total Gains per Share3.01.00.075.0%11.01.00.091.7%19.01.00.095.0%37.03.00.092.5%41.022.00.065.1%

Fundamentals of Li Kang Biomedical Co Ltd

About Li Kang Biomedical Co Ltd

Li Kang Biomedical Co., Ltd. manufactures and sells supplement, cosmeceutical, and hygienic drinks. It also engages in management and consulting of tourism factory business; and offers telemarketing services. The company was formerly known as BAFO Technologies Corporation and changed its name to Li Kang Biomedical Co., Ltd. in September 2014. Li Kang Biomedical Co., Ltd. was founded in 1982 and is based in Tainan City, Taiwan.

Fundamental data was last updated by Penke on 2024-03-28 02:28:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Li Kang Biomedical Co Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Li Kang Biomedical Co Ltd earns for each NT$1 of revenue.

  • Above 10% is considered healthy but always compare Li Kang Biomedical Co Ltd to the Travel Services industry mean.
  • A Net Profit Margin of 18.1% means that NT$0.18 for each NT$1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Li Kang Biomedical Co Ltd:

  • The MRQ is 18.1%. The company is making a huge profit. +2
  • The TTM is 17.5%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ18.1%TTM17.5%+0.6%
TTM17.5%YOY16.1%+1.4%
TTM17.5%5Y14.9%+2.6%
5Y14.9%10Y14.7%+0.2%
Compared to industry (Travel Services)
PeriodCompanyIndustry (mean)+/- 
MRQ18.1%2.4%+15.7%
TTM17.5%0.9%+16.6%
YOY16.1%-15.0%+31.1%
5Y14.9%-31.9%+46.8%
10Y14.7%-21.2%+35.9%
1.1.2. Return on Assets

Shows how efficient Li Kang Biomedical Co Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Li Kang Biomedical Co Ltd to the Travel Services industry mean.
  • 3.7% Return on Assets means that Li Kang Biomedical Co Ltd generated NT$0.04 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Li Kang Biomedical Co Ltd:

  • The MRQ is 3.7%. Using its assets, the company is less efficient in making profit.
  • The TTM is 3.6%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ3.7%TTM3.6%+0.1%
TTM3.6%YOY4.1%-0.5%
TTM3.6%5Y3.1%+0.6%
5Y3.1%10Y3.1%0.0%
Compared to industry (Travel Services)
PeriodCompanyIndustry (mean)+/- 
MRQ3.7%0.8%+2.9%
TTM3.6%0.8%+2.8%
YOY4.1%-2.1%+6.2%
5Y3.1%-2.0%+5.1%
10Y3.1%-0.6%+3.7%
1.1.3. Return on Equity

Shows how efficient Li Kang Biomedical Co Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Li Kang Biomedical Co Ltd to the Travel Services industry mean.
  • 4.9% Return on Equity means Li Kang Biomedical Co Ltd generated NT$0.05 for each NT$1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Li Kang Biomedical Co Ltd:

  • The MRQ is 4.9%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 4.6%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ4.9%TTM4.6%+0.3%
TTM4.6%YOY5.2%-0.6%
TTM4.6%5Y4.0%+0.6%
5Y4.0%10Y4.3%-0.4%
Compared to industry (Travel Services)
PeriodCompanyIndustry (mean)+/- 
MRQ4.9%2.6%+2.3%
TTM4.6%2.3%+2.3%
YOY5.2%-5.9%+11.1%
5Y4.0%-8.8%+12.8%
10Y4.3%-3.2%+7.5%

1.2. Operating Efficiency of Li Kang Biomedical Co Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Li Kang Biomedical Co Ltd is operating .

  • Measures how much profit Li Kang Biomedical Co Ltd makes for each NT$1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Li Kang Biomedical Co Ltd to the Travel Services industry mean.
  • An Operating Margin of 0.0% means the company generated NT$0.00  for each NT$1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Li Kang Biomedical Co Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM5.6%-5.6%
TTM5.6%YOY19.8%-14.2%
TTM5.6%5Y16.2%-10.6%
5Y16.2%10Y9.5%+6.7%
Compared to industry (Travel Services)
PeriodCompanyIndustry (mean)+/- 
MRQ-4.0%-4.0%
TTM5.6%3.0%+2.6%
YOY19.8%-14.5%+34.3%
5Y16.2%-22.1%+38.3%
10Y9.5%-11.7%+21.2%
1.2.2. Operating Ratio

Measures how efficient Li Kang Biomedical Co Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Travel Services industry mean).
  • An Operation Ratio of 1.10 means that the operating costs are NT$1.10 for each NT$1 in net sales.

Let's take a look of the Operating Ratio trends of Li Kang Biomedical Co Ltd:

  • The MRQ is 1.098. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.113. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.098TTM1.113-0.015
TTM1.113YOY1.219-0.106
TTM1.1135Y1.168-0.055
5Y1.16810Y0.820+0.348
Compared to industry (Travel Services)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0981.093+0.005
TTM1.1131.166-0.053
YOY1.2191.342-0.123
5Y1.1681.617-0.449
10Y0.8201.322-0.502

1.3. Liquidity of Li Kang Biomedical Co Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Li Kang Biomedical Co Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Travel Services industry mean).
  • A Current Ratio of 3.24 means the company has NT$3.24 in assets for each NT$1 in short-term debts.

Let's take a look of the Current Ratio trends of Li Kang Biomedical Co Ltd:

  • The MRQ is 3.243. The company is very able to pay all its short-term debts. +2
  • The TTM is 2.926. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ3.243TTM2.926+0.317
TTM2.926YOY2.404+0.522
TTM2.9265Y2.443+0.483
5Y2.44310Y1.375+1.068
Compared to industry (Travel Services)
PeriodCompanyIndustry (mean)+/- 
MRQ3.2431.094+2.149
TTM2.9261.086+1.840
YOY2.4041.146+1.258
5Y2.4431.203+1.240
10Y1.3751.254+0.121
1.3.2. Quick Ratio

Measures if Li Kang Biomedical Co Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Li Kang Biomedical Co Ltd to the Travel Services industry mean.
  • A Quick Ratio of 1.81 means the company can pay off NT$1.81 for each NT$1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Li Kang Biomedical Co Ltd:

  • The MRQ is 1.809. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.589. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.809TTM1.589+0.220
TTM1.589YOY1.043+0.545
TTM1.5895Y0.965+0.624
5Y0.96510Y0.591+0.374
Compared to industry (Travel Services)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8090.601+1.208
TTM1.5890.622+0.967
YOY1.0430.792+0.251
5Y0.9650.936+0.029
10Y0.5910.773-0.182

1.4. Solvency of Li Kang Biomedical Co Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Li Kang Biomedical Co Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Li Kang Biomedical Co Ltd to Travel Services industry mean.
  • A Debt to Asset Ratio of 0.24 means that Li Kang Biomedical Co Ltd assets are financed with 23.8% credit (debt) and the remaining percentage (100% - 23.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Li Kang Biomedical Co Ltd:

  • The MRQ is 0.238. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.212. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.238TTM0.212+0.027
TTM0.212YOY0.209+0.003
TTM0.2125Y0.223-0.012
5Y0.22310Y0.287-0.064
Compared to industry (Travel Services)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2380.648-0.410
TTM0.2120.649-0.437
YOY0.2090.661-0.452
5Y0.2230.636-0.413
10Y0.2870.577-0.290
1.4.2. Debt to Equity Ratio

Measures if Li Kang Biomedical Co Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Li Kang Biomedical Co Ltd to the Travel Services industry mean.
  • A Debt to Equity ratio of 31.3% means that company has NT$0.31 debt for each NT$1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Li Kang Biomedical Co Ltd:

  • The MRQ is 0.313. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.270. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.313TTM0.270+0.043
TTM0.270YOY0.267+0.003
TTM0.2705Y0.290-0.020
5Y0.29010Y0.461-0.171
Compared to industry (Travel Services)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3131.462-1.149
TTM0.2701.743-1.473
YOY0.2671.478-1.211
5Y0.2901.656-1.366
10Y0.4611.493-1.032

2. Market Valuation of Li Kang Biomedical Co Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every NT$1 in earnings Li Kang Biomedical Co Ltd generates.

  • Above 15 is considered overpriced but always compare Li Kang Biomedical Co Ltd to the Travel Services industry mean.
  • A PE ratio of 15.39 means the investor is paying NT$15.39 for every NT$1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Li Kang Biomedical Co Ltd:

  • The EOD is 14.198. Based on the earnings, the company is underpriced. +1
  • The MRQ is 15.386. Based on the earnings, the company is fair priced.
  • The TTM is 18.088. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD14.198MRQ15.386-1.188
MRQ15.386TTM18.088-2.702
TTM18.088YOY15.403+2.685
TTM18.0885Y22.982-4.894
5Y22.98210Y24.159-1.178
Compared to industry (Travel Services)
PeriodCompanyIndustry (mean)+/- 
EOD14.1987.797+6.401
MRQ15.3867.308+8.078
TTM18.0881.813+16.275
YOY15.403-5.764+21.167
5Y22.9822.868+20.114
10Y24.15910.921+13.238
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Li Kang Biomedical Co Ltd:

  • The EOD is 7.507. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 8.134. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 148.381. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD7.507MRQ8.134-0.628
MRQ8.134TTM148.381-140.247
TTM148.381YOY17.717+130.664
TTM148.3815Y28.409+119.972
5Y28.40910Y14.204+14.204
Compared to industry (Travel Services)
PeriodCompanyIndustry (mean)+/- 
EOD7.5073.815+3.692
MRQ8.1344.054+4.080
TTM148.3814.130+144.251
YOY17.717-3.777+21.494
5Y28.409-1.447+29.856
10Y14.2041.940+12.264
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Li Kang Biomedical Co Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Travel Services industry mean).
  • A PB ratio of 3.03 means the investor is paying NT$3.03 for each NT$1 in book value.

Let's take a look of the Price to Book Ratio trends of Li Kang Biomedical Co Ltd:

  • The EOD is 2.794. Based on the equity, the company is underpriced. +1
  • The MRQ is 3.028. Based on the equity, the company is fair priced.
  • The TTM is 3.334. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD2.794MRQ3.028-0.234
MRQ3.028TTM3.334-0.306
TTM3.334YOY2.971+0.363
TTM3.3345Y2.921+0.413
5Y2.92110Y5.136-2.216
Compared to industry (Travel Services)
PeriodCompanyIndustry (mean)+/- 
EOD2.7942.904-0.110
MRQ3.0283.053-0.025
TTM3.3343.219+0.115
YOY2.9713.178-0.207
5Y2.9213.154-0.233
10Y5.1363.423+1.713
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Li Kang Biomedical Co Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.8500.458+86%0.597+42%0.249+241%0.463+84%
Book Value Per Share--19.25218.398+5%16.198+19%15.715+23%12.628+52%
Current Ratio--3.2432.926+11%2.404+35%2.443+33%1.375+136%
Debt To Asset Ratio--0.2380.212+13%0.209+14%0.223+7%0.287-17%
Debt To Equity Ratio--0.3130.270+16%0.267+17%0.290+8%0.461-32%
Dividend Per Share----0%0.763-100%1.041-100%0.693-100%
Eps--0.9470.883+7%0.856+11%0.642+47%0.577+64%
Free Cash Flow Per Share--1.7920.714+151%1.181+52%0.733+144%0.733+144%
Free Cash Flow To Equity Per Share--1.7920.714+151%0.669+168%0.372+381%0.372+381%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.925+8%
Intrinsic Value_10Y_max--54.055--------
Intrinsic Value_10Y_min--45.992--------
Intrinsic Value_1Y_max--3.437--------
Intrinsic Value_1Y_min--3.375--------
Intrinsic Value_3Y_max--11.836--------
Intrinsic Value_3Y_min--11.269--------
Intrinsic Value_5Y_max--22.054--------
Intrinsic Value_5Y_min--20.340--------
Market Cap1760594240.000-8%1907855840.0002002757760.000-5%1577336178.120+21%1510249356.376+26%1612333551.856+18%
Net Profit Margin--0.1810.175+3%0.161+12%0.149+21%0.147+23%
Operating Margin---0.056-100%0.198-100%0.162-100%0.095-100%
Operating Ratio--1.0981.113-1%1.219-10%1.168-6%0.820+34%
Pb Ratio2.794-8%3.0283.334-9%2.971+2%2.921+4%5.136-41%
Pe Ratio14.198-8%15.38618.088-15%15.4030%22.982-33%24.159-36%
Price Per Share53.800-8%58.30061.200-5%48.200+21%46.150+26%49.269+18%
Price To Free Cash Flow Ratio7.507-8%8.134148.381-95%17.717-54%28.409-71%14.204-43%
Price To Total Gains Ratio63.285-8%68.57922.166+209%41.148+67%41.486+65%61.260+12%
Quick Ratio--1.8091.589+14%1.043+73%0.965+87%0.591+206%
Return On Assets--0.0370.036+3%0.041-10%0.031+21%0.031+19%
Return On Equity--0.0490.046+7%0.052-6%0.040+24%0.043+14%
Total Gains Per Share--0.8500.458+86%1.360-37%1.291-34%1.156-26%
Usd Book Value--19720001.60018844830.125+5%16591629.200+19%16097043.815+23%12935161.635+52%
Usd Book Value Change Per Share--0.0270.014+86%0.019+42%0.008+241%0.014+84%
Usd Book Value Per Share--0.6030.576+5%0.507+19%0.492+23%0.395+52%
Usd Dividend Per Share----0%0.024-100%0.033-100%0.022-100%
Usd Eps--0.0300.028+7%0.027+11%0.020+47%0.018+64%
Usd Free Cash Flow--1835275.500731504.475+151%1209306.800+52%600662.650+206%300331.325+511%
Usd Free Cash Flow Per Share--0.0560.022+151%0.037+52%0.023+144%0.023+144%
Usd Free Cash Flow To Equity Per Share--0.0560.022+151%0.021+168%0.012+381%0.012+381%
Usd Market Cap55106599.712-8%59715887.79262686317.888-5%49370622.375+21%47270804.855+26%50466040.173+18%
Usd Price Per Share1.684-8%1.8251.916-5%1.509+21%1.444+26%1.542+18%
Usd Profit--970300.000868520.225+12%877135.550+11%650739.520+49%587150.440+65%
Usd Revenue--5375618.5004924890.675+9%5354279.725+0%4132567.170+30%3751672.775+43%
Usd Total Gains Per Share--0.0270.014+86%0.043-37%0.040-34%0.036-26%
 EOD+4 -4MRQTTM+27 -6YOY+24 -115Y+26 -910Y+29 -7

3.2. Fundamental Score

Let's check the fundamental score of Li Kang Biomedical Co Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1514.198
Price to Book Ratio (EOD)Between0-12.794
Net Profit Margin (MRQ)Greater than00.181
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.809
Current Ratio (MRQ)Greater than13.243
Debt to Asset Ratio (MRQ)Less than10.238
Debt to Equity Ratio (MRQ)Less than10.313
Return on Equity (MRQ)Greater than0.150.049
Return on Assets (MRQ)Greater than0.050.037
Total6/10 (60.0%)

3.3. Technical Score

Let's check the technical score of Li Kang Biomedical Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.826
Ma 20Greater thanMa 5053.760
Ma 50Greater thanMa 10054.932
Ma 100Greater thanMa 20056.199
OpenGreater thanClose54.200
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in TWD. All numbers in thousands.

Summary
Total Assets827,005
Total Liabilities196,973
Total Stockholder Equity630,032
 As reported
Total Liabilities 196,973
Total Stockholder Equity+ 630,032
Total Assets = 827,005

Assets

Total Assets827,005
Total Current Assets355,682
Long-term Assets471,323
Total Current Assets
Cash And Cash Equivalents 111,842
Short-term Investments 189,180
Net Receivables 9,267
Inventory 41,594
Total Current Assets  (as reported)355,682
Total Current Assets  (calculated)351,883
+/- 3,799
Long-term Assets
Property Plant Equipment 368,143
Long-term Assets  (as reported)471,323
Long-term Assets  (calculated)368,143
+/- 103,180

Liabilities & Shareholders' Equity

Total Current Liabilities109,689
Long-term Liabilities87,284
Total Stockholder Equity630,032
Total Current Liabilities
Short Long Term Debt 14,252
Accounts payable 17,358
Other Current Liabilities 662
Total Current Liabilities  (as reported)109,689
Total Current Liabilities  (calculated)32,272
+/- 77,417
Long-term Liabilities
Long term Debt 31,354
Capital Lease Obligations Min Short Term Debt55,836
Long-term Liabilities  (as reported)87,284
Long-term Liabilities  (calculated)87,190
+/- 94
Total Stockholder Equity
Retained Earnings 272,376
Total Stockholder Equity (as reported)630,032
Total Stockholder Equity (calculated)272,376
+/- 357,656
Other
Capital Stock268,065
Common Stock Shares Outstanding 27,725
Net Invested Capital 675,638
Net Working Capital 245,993
Property Plant and Equipment Gross 368,143



Balance Sheet

Currency in TWD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-06-302006-06-302005-06-30
> Total Assets 
742,837
780,671
583,882
616,540
439,616
454,155
438,894
384,546
330,303
306,682
252,833
220,899
154,663
140,218
153,963
144,489
133,649
142,308
182,805
187,312
188,804
177,693
147,566
152,410
139,121
116,010
111,791
96,570
137,604
320,897
324,374
338,969
358,580
364,262
526,729
517,635
527,458
534,923
554,768
563,202
570,757
561,877
596,061
608,401
633,570
584,362
609,850
628,656
641,649
584,332
626,438
614,388
613,387
612,135
644,766
681,771
645,936
589,298
616,072
632,867
692,010
667,971
688,839
715,245
728,400
790,048
827,005
827,005790,048728,400715,245688,839667,971692,010632,867616,072589,298645,936681,771644,766612,135613,387614,388626,438584,332641,649628,656609,850584,362633,570608,401596,061561,877570,757563,202554,768534,923527,458517,635526,729364,262358,580338,969324,374320,897137,60496,570111,791116,010139,121152,410147,566177,693188,804187,312182,805142,308133,649144,489153,963140,218154,663220,899252,833306,682330,303384,546438,894454,155439,616616,540583,882780,671742,837
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
273,570
177,603
207,671
231,016
248,304
195,444
241,993
233,527
236,248
226,792
262,564
268,412
235,667
182,841
216,227
233,745
296,598
271,198
309,291
341,007
357,405
314,659
355,682
355,682314,659357,405341,007309,291271,198296,598233,745216,227182,841235,667268,412262,564226,792236,248233,527241,993195,444248,304231,016207,671177,603273,57000000000000000000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
221,370
134,514
164,609
190,180
180,212
127,633
142,104
125,737
118,741
107,083
98,099
107,080
74,589
67,778
101,358
106,522
116,117
120,881
132,012
149,725
118,716
63,858
111,842
111,84263,858118,716149,725132,012120,881116,117106,522101,35867,77874,589107,08098,099107,083118,741125,737142,104127,633180,212190,180164,609134,514221,37000000000000000000000000000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,178
0
0
0
22,027
21,884
51,844
51,628
63,959
72,441
122,495
120,754
111,086
72,015
74,394
80,922
80,028
95,354
131,420
142,612
180,980
188,577
189,180
189,180188,577180,980142,612131,42095,35480,02880,92274,39472,015111,086120,754122,49572,44163,95951,62851,84421,88422,02700012,17800000000000000000000000000000000000000000000
       Net Receivables 
157,809
151,621
153,106
219,737
84,899
100,495
81,334
80,249
47,063
65,889
54,351
46,266
41,192
50,322
39,859
30,270
30,132
31,951
23,155
30,715
53,460
61,173
42,729
61,833
53,404
41,865
47,695
26,687
66,108
26,143
18,040
14,714
14,209
14,266
21,944
18,666
16,038
13,020
14,509
14,164
14,265
14,385
15,390
15,119
14,736
15,461
18,105
5,036
3,826
5,366
15,609
16,340
14,165
5,491
7,446
6,941
9,375
5,839
8,084
7,589
62,902
21,199
10,183
7,064
8,667
9,703
9,267
9,2679,7038,6677,06410,18321,19962,9027,5898,0845,8399,3756,9417,4465,49114,16516,34015,6095,3663,8265,03618,10515,46114,73615,11915,39014,38514,26514,16414,50913,02016,03818,66621,94414,26614,20914,71418,04026,14366,10826,68747,69541,86553,40461,83342,72961,17353,46030,71523,15531,95130,13230,27039,85950,32241,19246,26654,35165,88947,06380,24981,334100,49584,899219,737153,106151,621157,809
       Inventory 
0
203,280
0
0
187,017
183,261
196,762
172,887
134,242
121,792
101,845
90,327
45,336
40,665
40,856
48,997
46,318
50,334
42,207
46,949
49,012
41,811
43,887
43,471
41,297
42,638
34,967
33,073
4,856
26,375
26,004
22,575
21,208
25,956
37,477
29,909
19,422
15,624
24,231
27,692
24,587
30,602
24,113
28,146
24,982
27,332
24,430
24,813
28,349
29,436
29,272
39,007
38,824
41,106
31,382
30,586
35,998
33,425
31,125
36,292
34,217
30,515
33,650
37,871
44,290
47,676
41,594
41,59447,67644,29037,87133,65030,51534,21736,29231,12533,42535,99830,58631,38241,10638,82439,00729,27229,43628,34924,81324,43027,33224,98228,14624,11330,60224,58727,69224,23115,62419,42229,90937,47725,95621,20822,57526,00426,3754,85633,07334,96742,63841,29743,47143,88741,81149,01246,94942,20750,33446,31848,99740,85640,66545,33690,327101,845121,792134,242172,887196,762183,261187,01700203,2800
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
397,640
393,345
388,888
384,445
380,861
377,139
385,343
382,202
413,359
410,269
406,457
399,845
399,122
395,412
396,773
379,548
374,238
370,995
475,389
471,323
471,323475,389370,995374,238379,548396,773395,412399,122399,845406,457410,269413,359382,202385,343377,139380,861384,445388,888393,345397,64000000000000000000000000000000000000000000000000
       Property Plant Equipment 
250,889
225,491
51,311
77,881
84,450
86,271
70,242
65,945
57,096
53,782
48,505
43,740
10,178
5,333
4,515
3,739
3,251
5,525
6,717
7,591
7,971
7,759
6,524
5,869
5,617
5,257
4,950
4,649
4,223
1,416
13,357
35,950
94,861
93,892
373,244
369,469
366,094
362,239
357,848
353,118
348,532
344,779
342,140
337,913
333,547
405,945
401,427
396,942
392,699
388,294
384,132
380,354
376,642
374,129
370,656
369,223
367,116
365,617
362,405
359,952
357,505
355,191
276,678
274,607
272,483
368,908
368,143
368,143368,908272,483274,607276,678355,191357,505359,952362,405365,617367,116369,223370,656374,129376,642380,354384,132388,294392,699396,942401,427405,945333,547337,913342,140344,779348,532353,118357,848362,239366,094369,469373,24493,89294,86135,95013,3571,4164,2234,6494,9505,2575,6175,8696,5247,7597,9717,5916,7175,5253,2513,7394,5155,33310,17843,74048,50553,78257,09665,94570,24286,27184,45077,88151,311225,491250,889
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
469
507
643
704
673
121
0
1,694
1,549
1,404
1,353
1,203
1,168
1,007
846
686
526
365
204
547
493
438
471
409
358
306
254
203
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000002032543063584094714384935472043655266868461,0071,1681,2031,3531,4041,5491,694012167370464350746900000000000000000000000
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
397,640
393,345
388,888
384,445
355
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000355384,445388,888393,345397,64000000000000000000000000000000000000000000000000
> Total Liabilities 
523,816
599,408
268,254
214,671
268,097
286,643
247,577
196,711
154,455
159,210
124,346
113,339
74,606
68,926
49,648
50,026
50,315
63,244
59,373
73,457
83,791
78,390
62,450
79,110
93,565
81,700
87,502
70,706
68,734
69,739
96,932
103,678
103,192
101,201
246,435
227,295
219,102
217,629
213,964
207,816
218,772
146,385
150,380
143,044
199,993
138,014
142,931
144,277
191,967
123,497
143,003
126,613
161,866
135,249
136,463
162,207
177,144
115,440
124,072
125,093
188,485
129,071
118,702
119,850
147,754
187,836
196,973
196,973187,836147,754119,850118,702129,071188,485125,093124,072115,440177,144162,207136,463135,249161,866126,613143,003123,497191,967144,277142,931138,014199,993143,044150,380146,385218,772207,816213,964217,629219,102227,295246,435101,201103,192103,67896,93269,73968,73470,70687,50281,70093,56579,11062,45078,39083,79173,45759,37363,24450,31550,02649,64868,92674,606113,339124,346159,210154,455196,711247,577286,643268,097214,671268,254599,408523,816
   > Total Current Liabilities 
349,807
544,911
267,799
212,443
266,875
285,135
246,468
195,564
153,544
158,317
123,673
112,670
74,135
68,468
49,367
49,743
50,187
63,108
59,373
69,291
82,124
78,390
62,450
79,110
93,565
81,700
87,502
70,706
68,734
69,739
96,932
103,678
103,192
101,201
122,235
106,545
115,107
116,692
129,297
125,795
152,503
82,325
87,793
87,711
146,709
86,670
93,622
97,017
146,757
80,336
101,953
87,613
124,916
89,406
92,731
120,525
137,512
77,857
88,338
91,409
156,812
105,934
118,611
119,773
147,636
98,551
109,689
109,68998,551147,636119,773118,611105,934156,81291,40988,33877,857137,512120,52592,73189,406124,91687,613101,95380,336146,75797,01793,62286,670146,70987,71187,79382,325152,503125,795129,297116,692115,107106,545122,235101,201103,192103,67896,93269,73968,73470,70687,50281,70093,56579,11062,45078,39082,12469,29159,37363,10850,18749,74349,36768,46874,135112,670123,673158,317153,544195,564246,468285,135266,875212,443267,799544,911349,807
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,881
8,881
8,881
19,729
28,134
15,871
22,850
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000022,85015,87128,13419,7298,8818,8818,88100000000000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,881
8,881
8,881
19,729
28,134
15,871
22,850
21,580
6,590
12,009
14,105
13,595
17,030
25,571
7,869
12,559
16,121
11,863
18,550
18,930
20,747
26,078
14,252
14,25226,07820,74718,93018,55011,86316,12112,5597,86925,57117,03013,59514,10512,0096,59021,58022,85015,87128,13419,7298,8818,8818,88100000000000000000000000000000000000000000000
       Accounts payable 
210,363
221,976
144,061
97,685
132,451
162,950
109,583
117,593
96,932
105,102
79,647
73,789
46,814
57,275
39,735
37,249
32,700
36,239
30,304
34,434
50,549
50,962
37,155
54,910
55,544
45,182
48,926
35,753
33,024
28,485
22,752
25,575
26,561
22,392
24,427
11,462
15,679
16,570
24,771
24,697
23,034
26,612
26,524
30,537
34,571
28,467
26,748
16,916
12,683
11,409
30,386
20,291
18,651
33,411
27,520
24,949
24,682
11,572
29,464
33,446
67,888
39,043
43,903
23,157
44,587
10,766
17,358
17,35810,76644,58723,15743,90339,04367,88833,44629,46411,57224,68224,94927,52033,41118,65120,29130,38611,40912,68316,91626,74828,46734,57130,53726,52426,61223,03424,69724,77116,57015,67911,46224,42722,39226,56125,57522,75228,48533,02435,75348,92645,18255,54454,91037,15550,96250,54934,43430,30436,23932,70037,24939,73557,27546,81473,78979,647105,10296,932117,593109,583162,950132,45197,685144,061221,976210,363
       Other Current Liabilities 
22,383
24,575
31,538
46,575
39,653
30,068
50,644
28,618
16,027
19,085
11,509
15,592
12,397
6,632
6,048
9,886
10,111
10,974
13,931
10,102
8,129
8,261
8,628
10,034
9,354
9,518
11,576
7,953
8,710
23,254
74,180
78,103
76,631
78,809
84,008
81,283
87,193
87,887
93,061
90,515
120,633
46,877
52,433
48,977
76,165
20,709
25,718
407
645
554
33,644
34,892
77,962
21,917
24,984
61,180
74,991
12,736
19,006
22,782
52,313
26,534
35,168
635
103,049
618
662
662618103,04963535,16826,53452,31322,78219,00612,73674,99161,18024,98421,91777,96234,89233,64455464540725,71820,70976,16548,97752,43346,877120,63390,51593,06187,88787,19381,28384,00878,80976,63178,10374,18023,2548,7107,95311,5769,5189,35410,0348,6288,2618,12910,10213,93110,97410,1119,8866,0486,63212,39715,59211,50919,08516,02728,61850,64430,06839,65346,57531,53824,57522,383
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
47,260
45,210
43,161
41,050
39,000
36,950
45,843
43,732
41,682
39,632
37,583
35,734
33,684
31,673
23,137
91
77
118
89,285
87,284
87,28489,285118779123,13731,67333,68435,73437,58339,63241,68243,73245,84336,95039,00041,05043,16145,21047,26000000000000000000000000000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-8,881
-8,881
-8,881
-19,729
-28,134
-15,871
-22,850
0
0
0
0
0
0
0
0
0
0
0
0
0
0
55,569
55,836
55,83655,56900000000000000-22,850-15,871-28,134-19,729-8,881-8,881-8,88100000000000000000000000000000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
200
200
200
200
0
0
0
0
0
000002002002002000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
219,021
181,263
315,628
401,869
171,519
167,512
191,317
187,835
175,848
147,472
128,487
107,560
80,057
71,292
104,315
94,463
83,334
79,064
123,432
113,855
105,013
99,303
85,116
73,300
45,556
34,310
24,289
25,864
68,870
251,158
227,442
235,291
255,388
263,061
280,294
290,340
308,356
317,294
340,804
355,386
351,985
415,492
445,681
465,357
433,577
446,348
466,919
484,379
449,682
460,835
483,435
487,775
451,521
476,886
508,303
519,564
468,792
473,858
492,000
507,774
503,525
538,900
570,137
595,395
580,646
602,212
630,032
630,032602,212580,646595,395570,137538,900503,525507,774492,000473,858468,792519,564508,303476,886451,521487,775483,435460,835449,682484,379466,919446,348433,577465,357445,681415,492351,985355,386340,804317,294308,356290,340280,294263,061255,388235,291227,442251,15868,87025,86424,28934,31045,55673,30085,11699,303105,013113,855123,43279,06483,33494,463104,31571,29280,057107,560128,487147,472175,848187,835191,317167,512171,519401,869315,628181,263219,021
   Common Stock
347,571
347,571
392,928
558,107
558,107
558,107
558,107
338,107
338,107
338,107
338,107
338,107
488,107
488,107
688,107
688,107
688,107
139,384
186,734
186,734
186,734
186,734
186,734
186,734
186,734
186,734
186,734
57,000
77,000
200,000
200,000
200,000
200,000
200,000
200,000
200,000
200,000
222,000
222,000
222,000
222,000
222,000
222,000
222,000
222,000
222,000
222,000
222,000
222,000
222,000
222,000
222,000
222,000
222,000
222,000
222,000
222,000
222,000
222,000
222,000
222,000
233,100
233,100
0
233,100
0
0
00233,1000233,100233,100222,000222,000222,000222,000222,000222,000222,000222,000222,000222,000222,000222,000222,000222,000222,000222,000222,000222,000222,000222,000222,000222,000222,000222,000200,000200,000200,000200,000200,000200,000200,000200,00077,00057,000186,734186,734186,734186,734186,734186,734186,734186,734186,734139,384688,107688,107688,107488,107488,107338,107338,107338,107338,107338,107558,107558,107558,107558,107392,928347,571347,571
   Retained Earnings Total Equity0000000000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 0000000000000000000000000000000000000000000000000000000000000000000
   Capital Surplus 0000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000000-3,156-17,122-17,122
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,232
212
-2,158
-5,668
-3,838
5,882
-1,468
-6,328
0
24,797
0
0
0024,7970-6,328-1,4685,882-3,838-5,668-2,1582121,2320000000000000000000000000000000000000000000000000000000



Balance Sheet

Currency in TWD. All numbers in thousands.




Cash Flow

Currency in TWD. All numbers in thousands.




Income Statement

Currency in TWD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue629,379
Cost of Revenue-203,234
Gross Profit426,145426,145
 
Operating Income (+$)
Gross Profit426,145
Operating Expense-496,008
Operating Income133,371-69,863
 
Operating Expense (+$)
Research Development-
Selling General Administrative292,774
Selling And Marketing Expenses-
Operating Expense496,008292,774
 
Net Interest Income (+$)
Interest Income3,265
Interest Expense-618
Other Finance Cost-0
Net Interest Income2,647
 
Pretax Income (+$)
Operating Income133,371
Net Interest Income2,647
Other Non-Operating Income Expenses-
Income Before Tax (EBT)139,144133,371
EBIT - interestExpense = -618
110,993
111,611
Interest Expense618
Earnings Before Interest and Taxes (EBIT)-139,762
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax139,144
Tax Provision-28,151
Net Income From Continuing Ops110,993110,993
Net Income110,993
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net--2,647
 

Technical Analysis of Li Kang Biomedical Co Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Li Kang Biomedical Co Ltd. The general trend of Li Kang Biomedical Co Ltd is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Li Kang Biomedical Co Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Li Kang Biomedical Co Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 54.30 < 56.30 < 58.80.

The bearish price targets are: 53.02 > 53.00 > 51.34.

Tweet this
Li Kang Biomedical Co Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Li Kang Biomedical Co Ltd. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Li Kang Biomedical Co Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Li Kang Biomedical Co Ltd. The current macd is -0.33643218.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Li Kang Biomedical Co Ltd price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Li Kang Biomedical Co Ltd. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Li Kang Biomedical Co Ltd price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Li Kang Biomedical Co Ltd Daily Moving Average Convergence/Divergence (MACD) ChartLi Kang Biomedical Co Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Li Kang Biomedical Co Ltd. The current adx is 33.85.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Li Kang Biomedical Co Ltd shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Li Kang Biomedical Co Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Li Kang Biomedical Co Ltd. The current sar is 54.50.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Li Kang Biomedical Co Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Li Kang Biomedical Co Ltd. The current rsi is 44.83. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Li Kang Biomedical Co Ltd Daily Relative Strength Index (RSI) ChartLi Kang Biomedical Co Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Li Kang Biomedical Co Ltd. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Li Kang Biomedical Co Ltd price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Li Kang Biomedical Co Ltd Daily Stochastic Oscillator ChartLi Kang Biomedical Co Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Li Kang Biomedical Co Ltd. The current cci is 61.03.

Li Kang Biomedical Co Ltd Daily Commodity Channel Index (CCI) ChartLi Kang Biomedical Co Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Li Kang Biomedical Co Ltd. The current cmo is -4.22121432.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Li Kang Biomedical Co Ltd Daily Chande Momentum Oscillator (CMO) ChartLi Kang Biomedical Co Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Li Kang Biomedical Co Ltd. The current willr is -37.5.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Li Kang Biomedical Co Ltd is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Li Kang Biomedical Co Ltd Daily Williams %R ChartLi Kang Biomedical Co Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Li Kang Biomedical Co Ltd.

Li Kang Biomedical Co Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Li Kang Biomedical Co Ltd. The current atr is 0.58418773.

Li Kang Biomedical Co Ltd Daily Average True Range (ATR) ChartLi Kang Biomedical Co Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Li Kang Biomedical Co Ltd. The current obv is 3,489,661.

Li Kang Biomedical Co Ltd Daily On-Balance Volume (OBV) ChartLi Kang Biomedical Co Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Li Kang Biomedical Co Ltd. The current mfi is 45.90.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Li Kang Biomedical Co Ltd Daily Money Flow Index (MFI) ChartLi Kang Biomedical Co Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Li Kang Biomedical Co Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-01STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-11-02STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-03MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-11-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-11-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-10STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-11-13WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-16STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-17STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-23STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-29WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-30BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-01STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-03CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-09CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-24CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-16MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-06MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-21MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

Li Kang Biomedical Co Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Li Kang Biomedical Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.826
Ma 20Greater thanMa 5053.760
Ma 50Greater thanMa 10054.932
Ma 100Greater thanMa 20056.199
OpenGreater thanClose54.200
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Li Kang Biomedical Co Ltd with someone you think should read this too:
  • Are you bullish or bearish on Li Kang Biomedical Co Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Li Kang Biomedical Co Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Li Kang Biomedical Co Ltd

I send you an email if I find something interesting about Li Kang Biomedical Co Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Li Kang Biomedical Co Ltd.

Receive notifications about Li Kang Biomedical Co Ltd in your mailbox!